Azienda Sanitaria Locale Br — Clinical Trial Site

26 Registered trials

7 Currently recruiting

Organisation

Azienda Sanitaria Locale Br

Location

Brindisi, Italy

Identifier

ORG-100044655

Address

Via Napoli 8, 72100, Italy

Departments

#1607: Centro Sclerosi Multipla U.O.C. Neurologia
Complex Operating Unit of Hematology and Transplantation
EMATOLOGIA
Medical oncology
Neurology
Oncologia Medica
Plastic Surgery and Burn Center
Presidio di Brindisi "Di Summa ‐ Perrino" Oncologia Medica
Presidio Ospedaliero "Antonio Perrino" - SC Oncologia Medica
U.O. Ematologia e Trapianti di Midollo
U.O.C di Ematologia
U.O.C. di Oncologia e Breast Unit
U.O.C. Ematologia e Trapianto
U.O.C. Ematologia - P.O. "A. Perrino
U.O.C. Oncologia Medica
UO di Oncologia Medica
UO EMATOLOGIA
UOC Oncologia
UOC Oncologia Medica

Clinical trials at this site (26)

Search interface

Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced br… Pending

2024-518026-32-00 Invasive Breast Cancer 5
Efficacy and safety of vamifeport in adult subjects with HFE-related hereditary hemochromatosis Pending

2025-523793-16-00 Homeostatic iron regulator gene-related hereditary hemo 4
A multicenter, prospective, randomized, double blind, placebo controlled, adaptive design study performed to evaluate the efficacy and the s… Recruiting

2024-519623-23-00 Venous leg ulcer 5 2025-10-20
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer Recruiting

2024-514822-21-00 Platinum-resistant Ovarian Cancer 5 2025-10-02
A phase III placebo-controlled efficacy and safety study of mocravimod as an adjunctive and maintenance treatment in AML patients undergoing… Recruiting

2024-512752-38-00 Adjunctive and maintenance treatment to HCT 5 2025-09-09
Phase II study to test whether a combination of three drugs—atezolizumab, vinorelbine, and weekly cyclophosphamide—can activate T-cells in p… Recruiting

2024-514031-20-00 Inoperable locally advanced or metastatic TNBC patients 4 2025-02-24
AGNOSTIC THERAPY IN A PHASE II, MULTICENTER, SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB (MEDI 4736) IN ASSOCIATION WITH CARBOPLA… Recruiting

2023-505078-13-00 EXTENSIVE STAGE ‐ EXTRAPULMONARY SMALL CELL CARCINOMA 4 2024-01-16
The study is aimed at evaluating the feasibility of a hypomethylating treatment combined with hematopoietic stem cell transplantation in com… Recruiting

2023-510515-19-00 Higher-risk-myelodysplastic syndromes 5 2020-11-27
Study to determine the efficacy of Gemtuzumab Ozogamicin, together with standard chemotherapy, on minimal residual disease levels, in adult … Recruiting

2023-510433-29-00 Favorable-intermediate-risk Acute Myeloid Leukemia 5 2020-09-24
A phase III study comparing the concurrent versus the sequential administration of chemotherapy and aromatase inhibitors, as adjuvant treatm… Ended

2024-519087-41-00 Breast cancer is the most common form of cancer among w 5 2025-02-03
A study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T) Ended

2024-512747-23-00 Transfusion-Dependent Alpha- or Beta-Thalassemia 5 2024-07-30
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-… Ended

2022-502446-27-00 Relapsed or Refractory Myeloma 5 2024-02-26
A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N… Ended

2022-502980-39-00 Estrogen receptor (ER)-positive, HER2-negative advanced 5 2024-01-25
A study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Non Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE) Ended

2024-512745-16-00 Non–Transfusion-Dependent Alpha- or Beta-Thalassemia 5 2022-04-13
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509372-41-00 Multiple Sclerosis 5 2022-01-30
Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden Follicular Lymph… Ended

2024-511636-27-00 Follicular Lymphoma 5 2021-12-01
The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and… Ended

2023-508968-30-00 Adult Philadelphia Chromosome-Positive Acute Lymphoblas 5 2021-09-08
Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f… Ended

2023-507961-24-00 High-Risk HER2-Positive Breast Cancer 5 2021-04-19
MITO 25.1: A randomized, molecular driven phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucapar… Ended

2024-516632-99-00 Advanced (stage III B-C-IV) ovarian, primary peritoneal 4 2021-03-17
Use of circulating tumor dna test to intensify post-operative treatment of patients with resected colon cancer. Halted

2024-515152-20-00 Stage III and high-risk stage II resected colon cancer 4 2023-03-02
A Window-of-Opportunity study of hormone therapy in premenopausal women with ER-positive/HER2-negative early breast cancer. Ended

2022-503013-32-00 ER-positive/HER2-negative early breast cancer 4 2024-01-29
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD (ACTIVATE study) Ended

2022-501783-18-00 Parkinson’s Disease 4 2023-07-21
The aim of the study is to evaluate the efficacy of Ponatinib, either alone or in combination with chemotherapy, in inducing remission in pa… Ended

2024-516868-28-00 Ph+ Acute Lymphoblastic Leukemia 4 2021-05-04
Comparison of two strategies that use the same drugs but with inverted sequence for the treatment of patients with metastatic colorectal can… Ended

2024-513296-41-00 Colorectal cancer spread at distance, RAS BRAF wild typ 4 2020-12-03